Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
Masahito KotakaRuihua XuKei MuroYoung Suk ParkSatoshi MoritaSatoru IwasaHiroyuki UetakeTomohiro NishinaHiroaki NozawaHiroshi MatsumotoKentaro YamazakiSae-Won HanWei WangJoong Bae AhnYanhong DengSang-Hee ChoYi BaKeun-Wook LeeTao ZhangTaroh SatohMarc E BuyseBaek-Yeol RyooLin ShenJunichi SakamotoTae Won KimPublished in: Chinese journal of cancer (2016)
The Asian XELIRI ProjecT is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second-line treatment option of mCRC. Trial registration ClinicalTrials.gov NCT01996306. UMIN000012263.